LANTHEUS HOLDINGS INC (LNTH) Stock Price, Forecast & Analysis
USA - NASDAQ:LNTH - US5165441032 - Common Stock
LNTH Key Statistics, Chart & Performance
The current stock price of LNTH is 53.5 USD. In the past month the price decreased by -7.28%. In the past year, price decreased by -40.9%.
LNTH Latest News, Press Relases and Analysis
LNTH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 17.96 | 14.35B | ||
| SOLV | SOLVENTUM CORP | 12.94 | 13.33B | ||
| ALGN | ALIGN TECHNOLOGY INC | 13.68 | 9.59B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 22.63 | 4.98B | ||
| HAE | HAEMONETICS CORP/MASS | 15.5 | 3.58B | ||
| ICUI | ICU MEDICAL INC | 16.84 | 3.31B | ||
| XRAY | DENTSPLY SIRONA INC | 6.49 | 2.05B | ||
| UFPT | UFP TECHNOLOGIES INC | 25.33 | 1.69B | ||
| NEOG | NEOGEN CORP | 19.73 | 1.29B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.27B | ||
| EMBC | EMBECTA CORP | 4.87 | 831.14M | ||
| BVS | BIOVENTUS INC - A | 11.85 | 577.93M |
Related stock screener links
About LNTH
Company Profile
Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The company is headquartered in North Billerica, Massachusetts and currently employs 808 full-time employees. The company went IPO on 2015-06-25. The firm classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.
Company Info
LANTHEUS HOLDINGS INC
331 Treble Cove Road
North Billerica MASSACHUSETTS 01862 US
CEO: Mary Anne Heino
Employees: 808
Phone: 19786718001
LANTHEUS HOLDINGS INC / LNTH FAQ
What does LNTH do?
Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The company is headquartered in North Billerica, Massachusetts and currently employs 808 full-time employees. The company went IPO on 2015-06-25. The firm classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.
What is the current price of LNTH stock?
The current stock price of LNTH is 53.5 USD. The price increased by 1.9% in the last trading session.
Does LANTHEUS HOLDINGS INC pay dividends?
LNTH does not pay a dividend.
What is the ChartMill rating of LANTHEUS HOLDINGS INC stock?
LNTH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Is LANTHEUS HOLDINGS INC (LNTH) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LNTH.
Can you provide the ownership details for LNTH stock?
You can find the ownership structure of LANTHEUS HOLDINGS INC (LNTH) on the Ownership tab.
LNTH Technical Analysis
LNTH Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to LNTH. LNTH has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
LNTH Financial Highlights
Over the last trailing twelve months LNTH reported a non-GAAP Earnings per Share(EPS) of 5.96. The EPS decreased by -14.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.99% | ||
| ROA | 7.37% | ||
| ROE | 14.98% | ||
| Debt/Equity | 0.51 |
LNTH Forecast & Estimates
19 analysts have analysed LNTH and the average price target is 85.05 USD. This implies a price increase of 58.98% is expected in the next year compared to the current price of 53.5.
For the next year, analysts expect an EPS growth of -15.34% and a revenue growth -2.39% for LNTH